|
[PMID]: | 15860442 |
[Au] Autor: | Sano T; Kagawa M; Okuno M; Ishibashi N; Hashimoto M; Yamamoto M; Suzuki R; Kohno H; Matsushima-Nishiwaki R; Takano Y; Tsurumi H; Kojima S; Friedman SL; Moriwaki H; Tanaka T |
[Ad] Endereço: | Pharmaceutical Research Laboratories, Nikken Chemicals Co., Saitama, Japan. |
[Ti] Título: | Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. |
[So] Source: | Nutr Cancer;51(2):197-206, 2005. | [Is] ISSN: | 0163-5581 |
[Cp] País de publicação: | United States |
[La] Idioma: | eng |
[Ab] Resumo: | We investigated the preventive effects of a synthetic acyclic retinoid, NIK-333, on the early and late events of hepatocarcinogenesis in male F344 rats treated with 3'-methyl-4-dimethylaminoazobenzene (3'-MeDAB). NIK-333 was administered once a day on consecutive days at a dose of 10, 40, or 80 mg/kg body weight along with the supplementation with 3'-MeDAB-containing diet for 16 wk. Animals from each group were sacrificed at 4 and 16 wk after the commencement of the experiment to determine the effect of NIK-333 on the early and late stages of carcinogenesis, respectively. NIK-333 suppressed the emergence of both oval-like cells expressing transforming growth factor (TGF)-alpha, putative progenitors of hepatocellular carcinoma (HCC), and activated hepatic stellate cells, major matrix-producing cells of the liver, in the early stage and inhibited the incidence of HCC in the late phase. These results suggest that NIK-333 is a promising drug for the chemoprevention of HCC by uniquely suppressing the early events of hepatocarcinogenesis, that is, development of both oval-like cells and fibrogenesis. |
[Mh] Termos MeSH primário: |
Actinas/metabolismo Adenoma/prevenção & controle Antineoplásicos/uso terapêutico Carcinoma/prevenção & controle Neoplasias Hepáticas Experimentais/prevenção & controle Fator de Crescimento Transformador alfa/metabolismo Tretinoína/análogos & derivados
|
[Mh] Termos MeSH secundário: |
Actinas/efeitos dos fármacos Adenoma/induzido quimicamente Animais Antineoplásicos/química Carcinoma/induzido quimicamente Modelos Animais de Doenças Progressão da Doença Relação Dose-Resposta a Droga Fibrose/prevenção & controle Fígado/efeitos dos fármacos Fígado/metabolismo Neoplasias Hepáticas Experimentais/induzido quimicamente Masculino Metildimetilaminoazobenzeno/administração & dosagem Metildimetilaminoazobenzeno/análogos & derivados Ratos Ratos Endogâmicos F344 Retinoides/uso terapêutico Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos Fatores de Tempo Fator de Crescimento Transformador alfa/efeitos dos fármacos Tretinoína/química Tretinoína/uso terapêutico
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S. |
[Nm] Nome de substância:
| 0 (Actins); 0 (Antineoplastic Agents); 0 (Retinoids); 0 (Transforming Growth Factor alpha); 0 (smooth muscle actin, rat); 11ALM7A4RV ((2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid); 3010-53-5 (3'-methyl-4-diethylaminoazobenzene); 55-80-1 (Methyldimethylaminoazobenzene); 5688UTC01R (Tretinoin); 81485-25-8 (3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) |
[Em] Mês de entrada: | 0510 |
[Cu] Atualização por classe: | 141120 |
[Lr] Data última revisão:
| 141120 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 050430 |
[St] Status: | MEDLINE |
|
|
|